

Diabetes & its Complications

From Palm-Mill Aqueous Side Streams to Precision Metabolic Nutrition: Oil Palm Phenolics, the Gut Microbiome, Metabolic Endotoxemia, and Insulin Resistance in Obesity and Type 2 Diabetes—A Translational Review

Loso Judijanto*

IPOSS Jakarta, Indonesia.

ORCID: 0009-0007-7766-0647

***Correspondence:**

Loso Judijanto, IPOSS Jakarta, Indonesia.

Received: 11 Aug 2026; **Accepted:** 19 Sep 2026; **Published:** 02 Oct 2026

Citation: Loso Judijanto. From Palm-Mill Aqueous Side Streams to Precision Metabolic Nutrition: Oil Palm Phenolics, the Gut Microbiome, Metabolic Endotoxemia, and Insulin Resistance in Obesity and Type 2 Diabetes—A Translational Review. *Diabetes Complications*. 2026; 10(3); 1-19.

ABSTRACT

Oil palm phenolics (OPP), recovered from aqueous side streams generated during oil-palm fruit processing, provide an unusual link between circular bioeconomy, phytochemical biotechnology, microbiome science, and metabolic medicine. This qualitative literature review critically evaluates whether OPP could progress from an underutilized palm-processing fraction to a microbiome-mediated nutritional intervention for obesity, prediabetes, and type 2 diabetes mellitus (T2DM). The review integrates evidence concerning OPP composition and human safety, gastrointestinal transformation of dietary polyphenols, microbial ecology, short-chain fatty acids, bile-acid metabolism, phenolic microbial metabolites, intestinal-barrier integrity, lipopolysaccharide-mediated metabolic endotoxemia, chronic inflammation, and insulin signaling. Direct clinical evidence remains limited: human research principally establishes short-term OPP safety rather than therapeutic efficacy. Nevertheless, experimental evidence demonstrates that palm-derived phenolic residues can alter obese-human fecal microbial communities and generate microbial phenolic metabolites. Broader human polyphenol research further supports modulation of microbiota and metabolic-endotoxemia-related endpoints, although effects on body weight, inflammation, and glycemic outcomes remain heterogeneous. This review proposes an integrated OPP–microbiome–intestinal barrier–metabolic inflammation–insulin resistance axis and identifies a translational evidence ladder from chemical standardization through microbiome-stratified clinical trials. OPP should currently be viewed as a promising microbiome-active candidate rather than an established antidiabetic nutraceutical.

Keywords

Oil palm phenolics, Gut microbiome, Metabolic endotoxemia, Obesity, Type 2 diabetes, Polyphenols, Intestinal barrier, Insulin resistance, Short-chain fatty acids, Precision nutrition.

JEL Classification: I12; I15; Q16; Q53; L65

Introduction

Obesity and type 2 diabetes as multidimensional metabolic disorders

Obesity and type 2 diabetes mellitus (T2DM) are no longer adequately conceptualized as disorders caused only by excessive energy intake, insufficient physical activity, pancreatic dysfunction, or peripheral insulin resistance. Their pathophysiology involves

an interdependent network encompassing adipose-tissue inflammation, altered hepatic lipid and glucose metabolism, skeletal-muscle insulin resistance, endocrine disturbances, chronic low-grade inflammation, oxidative stress, immune dysregulation, dietary exposures, and gastrointestinal physiology. Contemporary models increasingly emphasize inter-organ crosstalk among the liver, adipose tissue, skeletal muscle, pancreas, intestine and central nervous system in the development and progression of T2DM [1]. Within this network, the intestinal microbiome is recognized as a metabolically active interface because gut microorganisms participate in nutrient fermentation, bile-acid modification, immune regulation, intestinal-barrier maintenance, and the production of metabolites capable of influencing distant organs [2-5].

The increasing sophistication of microbiome research has challenged earlier attempts to identify a universal “obese microbiome” or “diabetic microbiome”. Systematic comparisons show recurring microbial alterations in obesity and T2DM, but the direction and magnitude of specific taxonomic associations vary across populations, medications, diets, sequencing platforms, and analytical procedures [6-8]. Mechanistic syntheses likewise emphasize ecological function, metabolite production and host context rather than a single disease-defining taxonomic signature [9-11]. Particularly important is the cross-cohort analysis by Mei et al. [12], which examined 8,117 metagenomes from participants with T2DM, prediabetes, and normoglycemia across several geographical populations and found both species-level and strain-specific associations with disease. Such evidence suggests that microbial function and within-species variation may be more informative than simplistic measures such as the Firmicutes-to-Bacteroidetes ratio.

This complexity has important implications for nutrition. Individuals exposed to the same food or phytochemical intervention may not generate identical metabolic products because their intestinal microorganisms possess different enzymatic capacities. The biological effect of a dietary compound is therefore partly determined by the chemical structure that enters the gastrointestinal tract and partly by the microbial community capable of transforming it. Such host-microbial heterogeneity provides a conceptual foundation for precision metabolic nutrition and for investigating botanical compounds whose bioavailability is strongly influenced by intestinal microbial metabolism [13-15].

The intestinal barrier and metabolic endotoxemia

The intestinal epithelium separates a densely populated microbial ecosystem from host circulation. Barrier integrity depends on epithelial cells, intercellular tight junctions, mucus, antimicrobial peptides, secretory immunoglobulins, mucosal immune cells, microbial metabolites, and appropriate epithelial renewal. Metabolic disturbance can disrupt several of these components, increasing exposure of the host to luminal antigens and microbial products [16,17].

A particularly influential concept is metabolic endotoxemia, in which increased intestinal translocation of bacterial lipopolysaccharide (LPS) or related microbial signals contributes to systemic low-grade inflammation. LPS can activate Toll-like receptor 4 (TLR4) and downstream signaling pathways including nuclear factor kappa B (NF- κ B), thereby increasing expression of pro-inflammatory mediators. These signals can interfere with insulin receptor pathways in adipose tissue, skeletal muscle, and the liver, providing a plausible mechanistic bridge between intestinal dysfunction and insulin resistance [18-20].

Nevertheless, contemporary evidence requires a more nuanced interpretation of endotoxemia. LPS structures differ among bacterial species, especially in the lipid-A region that determines immunological potency. Anhê et al. [21] demonstrated that

metabolically relevant consequences depend on the type of LPS rather than simply its presence or total concentration. Accordingly, future nutritional intervention studies should avoid treating circulating LPS as a single self-explanatory biomarker and should, where possible, integrate endotoxin-related measurements with metagenomic information and markers of epithelial integrity [21].

From antioxidant polyphenols to microbiome-active compounds Polyphenols have traditionally been described primarily as antioxidants, yet this interpretation does not fully explain their pharmacology. Many dietary polyphenols have relatively low absorption in the upper gastrointestinal tract, and substantial fractions can reach the colon. There, microbial enzymes transform them through reactions including deconjugation, demethylation, dehydroxylation, decarboxylation, reduction, and aromatic-ring cleavage. The resulting low-molecular-weight compounds can possess different absorption profiles and biological activities from their parent molecules [22-25].

The relationship is reciprocal. Polyphenols can influence microbial growth and competition, whereas microorganisms determine the spectrum of metabolites generated from the ingested phenolics. Dietary polyphenols may therefore function partly as microbial ecological modifiers or “prebiotic-like” compounds rather than acting exclusively through direct systemic antioxidant activity [26-29].

Human evidence increasingly supports this interpretation while simultaneously demonstrating considerable heterogeneity. Meta-analyses of randomized controlled trials indicate that polyphenol interventions can modify microbiota-associated outcomes and may reduce circulating LPS, but changes in weight, conventional inflammatory markers, and clinical metabolic endpoints are less consistent [30,31]. A newer synthesis of 50 randomized trials also reported an overall shift toward increased fecal SCFA production, particularly butyrate, although the authors emphasized that microbial alterations should not automatically be interpreted as proof of clinical benefit [32]. Intervention duration, polyphenol class, dosage, food matrix, baseline metabolic status, and microbiome methodology all contribute to heterogeneity [33].

Oil palm phenolics as an underexplored metabolic-health candidate Oil palm phenolics (OPP) represent a particularly interesting candidate for investigation within this framework. Oil-palm fruit contains hydrophilic phenolic compounds, and aqueous fractions generated during processing can retain these bioactives. Chemical studies have detected several benzoic- and cinnamic-acid derivatives in palm-derived matrices, while OPP preparations used experimentally have contained compounds including caffeoylshikimic-acid derivatives, protocatechuic acid, and p-hydroxybenzoic acid [34,35].

This creates an important circular-bioeconomy opportunity. Palm-oil milling and refining generate considerable side streams whose value is usually substantially lower than that of primary

oil products. Recovery of phytonutrients from such streams could create additional value while reducing material losses, although recovery efficiency, purification requirements, contaminant control, stability, and commercial feasibility remain important considerations [36-38].

The biomedical evidence is considerably less mature than the industrial opportunity. A phase I randomized, double-blind, placebo-controlled trial involving 100 healthy volunteers evaluated OPP doses of 250, 1,000, and 1,500 mg/day for two months. No serious treatment-related safety signal emerged, providing an important first human tolerability benchmark. However, the trial was not designed to determine whether OPP improves obesity, insulin resistance, or diabetes, and its results therefore cannot be interpreted as therapeutic evidence [39].

Of particular relevance to the present review, Chuaykarn et al. [40] examined palm-derived phenolic residue in an experimental system using fecal microbiota from individuals with obesity. The phenolic material modified microbial profiles and was associated with changes in microbial metabolites, including formation of 3-(3-hydroxyphenyl) propionic acid. This study provides an unusually direct bridge between palm-derived phenolics and the microbiome. However, because the work was based on fecal microbial fermentation rather than a clinical OPP intervention, it demonstrates mechanistic plausibility rather than therapeutic efficacy [40].

Aim of the review

The central question of this review is therefore whether OPP should be conceptualized not merely as an antioxidant mixture but as a potential microbiome-mediated metabolic intervention. The review evaluates the evidence through an integrated pathway consisting of OPP chemistry, gastrointestinal transformation, microbial ecological modulation, microbial metabolites, intestinal-barrier integrity, metabolic endotoxemia, inflammatory signaling, and insulin resistance.

The principal contribution is the development of a testable OPP–microbiome–intestinal barrier–metabolic inflammation–insulin resistance axis. Rather than presenting the pathway as established fact, the review distinguishes direct evidence from mechanistic extrapolation and identifies the experiments required to progress from biological plausibility to clinically meaningful evidence.

Literature Review

Oil palm phenolics: origin and chemical identity

Oil palm contains multiple classes of phytonutrients distributed across lipid and aqueous fractions. Although tocopherols, tocotrienols, carotenoids, and related lipid-soluble compounds have historically received greater research attention, hydrophilic phenolics are increasingly recognized as another potentially valuable component. Analyses of crude and refined palm products have identified gallic, protocatechuic, p-hydroxybenzoic, vanillic, syringic, caffeic, coumaric, and ferulic acids, with concentrations

varying strongly according to the matrix and degree of refining [34].

OPP obtained from aqueous processing streams is chemically different from the lipid fraction of palm oil and should not be conflated with the biological effects of dietary palm oil itself. The most relevant translational unit is a defined phenolic preparation whose chemical fingerprint, extraction procedure, and dose are specified. The phase I OPP preparation, for example, represented a standardized encapsulated intervention rather than consumption of conventional crude or refined palm oil [39].

Variation in extraction conditions presents a major challenge. Solvent composition, temperature, membrane separation, concentration, drying, storage, and the original characteristics of the palm fruit can alter phenolic yields and molecular profiles. Recovery research involving palm-oil mill and refinery by-products therefore has implications not only for process economics but also for biological reproducibility [36,38].

For nutritional and clinical development, OPP will require a reproducible chemical specification. Total phenolic content is useful for broad characterization but insufficient as the sole quality marker because preparations with similar total concentrations could contain materially different constituent profiles. Future clinical-grade OPP should ideally be characterized by quantitative LC-MS/MS fingerprinting, predefined marker compounds, stability specifications, contaminant limits, microbial safety standards, and batch-release criteria.

Circularity and value recovery from palm-processing side streams. The possibility of recovering OPP changes the conceptual treatment of palm-mill aqueous side streams. Conventional environmental management focuses on reducing biochemical oxygen demand, color, organic loading, and other pollution characteristics. A biorefinery model instead asks whether selected constituents can be recovered before or alongside conventional wastewater treatment. Such valorization strategies are increasingly important in industries seeking to reduce waste while expanding the economic value obtained from existing feedstocks [36].

This circularity narrative is attractive but should not be allowed to substitute for biomedical evidence. A compound may be technically recoverable and environmentally advantageous without exerting clinically meaningful effects. Conversely, a bioactive compound may show therapeutic promise yet prove commercially impractical because recovery, purification, stability, or regulatory costs are excessive. Industrial feasibility and biomedical efficacy are therefore distinct questions that must eventually be integrated but initially evaluated independently.

Research on microalgal and physicochemical treatment of palm-mill effluents further illustrates that phenolic compounds participate in complex aqueous matrices and may be altered during environmental processing. The fate of these molecules reinforces

the importance of defining at which stage phenolics should be recovered if they are intended for high-value applications [37].

The translational pathway from palm-processing side stream to a clinically testable OPP formulation is summarized in Figure 1. The pathway separates upstream circular-bioeconomy valorization from downstream biomedical validation, emphasizing that recovery of a phenolic fraction creates a candidate ingredient but does not by itself establish health efficacy.

The left side of Figure 1 represents industrial transformation from low-value aqueous material to a chemically defined preparation. The right side represents biomedical translation. The critical transition occurs at chemical standardization: without a reproducible OPP fingerprint, results from toxicological, microbiome, pharmacokinetic, and clinical studies cannot be compared reliably across batches or manufacturers.

Gastrointestinal bioaccessibility and microbial biotransformation
The gastrointestinal fate of polyphenols provides the mechanistic basis for expecting microbiome involvement. Although individual phenolics vary considerably, many are incompletely absorbed in the stomach and small intestine. Parent compounds may undergo glucuronidation, sulfation, methylation, hydrolysis, and other host transformations, while an unabsorbed fraction continues into the colon [22-24].

Once in the colon, compounds encounter microbial communities containing diverse enzymatic systems. Microbial deconjugation can release aglycones, whereas reduction, dehydroxylation, demethylation, decarboxylation, and aromatic-ring cleavage can generate smaller phenolic acids. These microbial derivatives may enter the portal circulation, undergo additional hepatic metabolism, and eventually reach peripheral tissues. Consequently, biological

exposure should be viewed as a mixture of parent compounds, host conjugates, microbial metabolites, and secondary host conjugates [25,41].

This process can explain why relatively low concentrations of intact polyphenols in plasma do not necessarily imply biological irrelevance. The microbiome effectively acts as an additional metabolic organ capable of producing molecules that were not present in the original food or supplement. Furthermore, the spectrum of generated metabolites differs among individuals according to microbial composition and enzymatic capacity, contributing to the phenomenon of metatypes [42].

For OPP, this reasoning is especially compelling because the mixture contains low-molecular-weight phenolic acids and caffeoyl-related compounds that could participate in microbial transformations. The *ex vivo* findings of Chuaykarn et al. [40] suggest that palm-derived phenolic material can generate identifiable microbial metabolites, but *in vivo* human studies are required to determine whether similar metabolites appear in stool, plasma, or urine following standardized OPP ingestion.

Polyphenols as ecological modifiers of the microbiome

Dietary polyphenols can affect microbial communities through several non-exclusive mechanisms. Some phenolics inhibit bacterial enzymes or membranes and can exert selective antimicrobial pressure. Others serve as substrates or generate metabolites that support specific microbial groups. Polyphenols may also modify intestinal pH, mucosal signaling, substrate competition, and cross-feeding relationships between bacterial taxa [26,43].

This has led to the concept of polyphenols as potential prebiotic-like compounds. However, the term should be used cautiously because a formal prebiotic requires evidence that a substrate is selectively




Figure 1: From palm-processing aqueous side stream to standardized OPP intervention.

utilized by host microorganisms and confers a demonstrable health benefit. Many studies document microbial shifts after polyphenol ingestion, but microbial modification alone does not establish health benefit or selective utilization [27,29].

Reviews of obesity-related polyphenol interventions describe increases in taxa such as *Akkermansia*, *Bifidobacterium*, *Lactobacillus*, and selected butyrate-producing organisms in some models, together with reductions in potentially pro-inflammatory taxa. Yet these changes are not universal across compounds or studies. The anti-obesity role of polyphenols is therefore better conceptualized as context-dependent ecological modulation than as predictable enrichment of a fixed set of “good bacteria” [28].

Recent meta-analytic evidence strengthens but also qualifies this interpretation. Mao et al. [30] reported microbiota and LPS-related changes across randomized polyphenol interventions in overweight or obese individuals. González-Gómez et al. [31] found reductions in circulating LPS and increases in acetate and butyrate but no significant pooled reduction in body mass or BMI. Alshatari and Ziarno [32], synthesizing 50 randomized trials involving 2,042 adults, reported favorable shifts in several microbial groups and higher fecal butyrate overall while cautioning that the evidence remains heterogeneous and does not establish causality between microbial change and clinical improvement.

These findings have two implications for OPP. First, an early OPP trial should not use body weight as its only or primary indicator of biological activity. Second, shotgun metagenomic and metabolomic endpoints will likely be more informative than broad taxonomic ratios.

Microbial dysbiosis in obesity and T2DM

Studies comparing individuals with and without obesity have reported differences in microbial richness, diversity, composition, and functional potential, although the results vary substantially. Crovesy, Masterson and Rosado [6] concluded that no single compositional signature consistently distinguishes all adults with obesity. This heterogeneity is expected because obesity encompasses different dietary patterns, adiposity distributions, metabolic phenotypes, medication use, and geographical environments.

T2DM shows similar complexity. Reviews have identified alterations in butyrate-producing bacteria, facultative anaerobes, mucin-associated species, and pathways related to amino acids, carbohydrates, and oxidative stress, but the precise microbial signatures differ among studies [7,8,18,44,45].

The analysis of Mei et al. [12] is especially instructive because its strain-level resolution demonstrates that organisms classified within the same species may differ in their association with diabetes. Functional pathways related to glucose metabolism and other processes also varied. This indicates that precision microbiome research should move beyond the assumption that

the abundance of a genus or species alone predicts host metabolic effects.

Baars et al. [5] further emphasized that the gut microbiome can influence both T2DM pathophysiology and treatment responses. Microbial metabolites may alter insulin sensitivity and host inflammatory status, while glucose-lowering drugs themselves can alter intestinal ecology. Accordingly, an OPP intervention in T2DM would enter an already pharmacologically modified microbial ecosystem.

Intestinal permeability as a mechanistic bridge

The intestinal barrier occupies a strategic position between the microbiome and systemic metabolism. Disruption of tight-junction regulation, mucus integrity, antimicrobial defense, or epithelial homeostasis can increase host exposure to bacterial products. Human evidence supports the presence of altered barrier-related biomarkers in T2DM, including serum measures related to LPS, zonulin, and intestinal fatty-acid-binding protein, although each biomarker has methodological limitations [16].

Barrier dysfunction can interact bidirectionally with dysbiosis. Reduced butyrate availability, altered bile acids, inflammatory microbial products, and changes in mucus-degrading organisms can impair barrier function, whereas inflammation and altered intestinal physiology can in turn reshape the microbiome. This feedback-loop model is more plausible than a simple unidirectional sequence from dysbiosis to disease [17,46].

Experimental polyphenol evidence provides mechanistic analogues. Phlorizin reduced high-fat-diet-associated metabolic endotoxemia and insulin resistance while modulating gut microbiota and intestinal-barrier integrity in an experimental model [47]. Polyphenols from Fu brick tea similarly improved intestinal oxidative stress, barrier-related measures, microbial composition, and obesity phenotypes in animal experiments, with fecal-microbiota-transfer approaches providing evidence for microbiome dependence [48].

Chlorogenic-acid research also supports links among polyphenols, microbiota, and endotoxemia-associated pathways [49]. These findings cannot be directly transferred to OPP, because different phenolics have distinct pharmacological properties. Nevertheless, they identify measurable pathways for testing whether OPP acts through similar mechanisms.

Metabolic endotoxemia and inflammatory signaling

LPS is a structural component of Gram-negative bacterial outer membranes. When pro-inflammatory forms of LPS enter the circulation, recognition through the LPS-binding protein/CD14/TLR4 system can activate downstream pathways such as MyD88, NF- κ B, and inflammatory kinases. Increased inflammatory cytokine signaling can impair insulin receptor substrate activity and contribute to reduced PI3K/Akt signaling, creating a potential link between microbial translocation and metabolic dysfunction [20].

The relationship is nevertheless more complex than “more Gram-negative bacteria equals more endotoxemia”. Anhê et al. [21] demonstrated that LPS originating from different bacterial species can produce markedly different metabolic and immunological effects. A microbiome enriched in bacteria producing weakly agonistic LPS may therefore differ biologically from one generating strongly inflammatory LPS even if conventional abundance measures appear similar.

Future OPP research should consequently combine several endpoints. Plasma LPS or LPS-binding protein could be integrated with intestinal-permeability assays, inflammatory mediators, stool metagenomics, and analysis of microbial pathways involved in LPS biosynthesis. This multidimensional approach would make it possible to determine whether OPP decreases microbial translocation, alters the inflammatory potential of the microbial community, or both.

The proposed OPP–microbiome–intestinal barrier–metabolic inflammation–insulin resistance pathway is summarized in Figure 2. This framework is explicitly hypothesis-generating: it integrates individually supported biological links while recognizing that the complete pathway has not yet been demonstrated in patients receiving OPP.

Figure 2 shows that evidence supporting the individual links varies in strength. Direct evidence exists for human OPP tolerability and experimental OPP–microbiome interaction, whereas evidence for improved barrier integrity, lower endotoxemia, and better insulin sensitivity comes predominantly from broader microbiome and polyphenol research. This graded evidence structure should remain visible throughout interpretation of the figure.

Short-chain fatty acids

SCFAs are major microbial fermentation products that participate in intestinal and systemic signaling. Acetate, propionate, and butyrate differ in tissue distribution and physiological effects. Butyrate serves as an important energy substrate for colonocytes and can influence epithelial integrity, while SCFAs can signal through G-protein-coupled receptors and affect enteroendocrine, immune, hepatic, and adipose functions [50,51].

The relationship between SCFAs and obesity is not uniformly linear. High fecal SCFA concentration can reflect increased production, altered absorption, changed transit time, or reduced utilization. Consequently, higher fecal SCFAs should not automatically be interpreted as improved metabolic health. Physiological interpretation requires considering circulating levels, microbial pathways, diet, host absorption, and clinical phenotype [50].

Polyphenol supplementation nevertheless appears capable of influencing SCFA profiles. González-Gómez et al. [31] reported pooled increases in acetate and butyrate in overweight and obese adults, whereas Mao et al. [30] reached more conservative conclusions for SCFA outcomes. Alshatari and Ziarno [32] identified a more consistent positive association with fecal butyrate across 50 RCTs. Differences among these meta-analyses highlight the importance of study selection, analytical method, intervention type, and publication date.

An OPP trial should therefore measure SCFAs but avoid using them as standalone indicators of efficacy. The stronger strategy would link SCFA changes to microbial genes, intestinal-barrier markers, inflammatory mediators, and glucose-homeostasis endpoints.




Figure 2: Proposed OPP–microbiome–intestinal barrier–metabolic inflammation–insulin resistance axis.

Bile-acid metabolism

Bile acids constitute another major communication pathway between the gut microbiome and host metabolism. Primary bile acids synthesized from cholesterol are secreted into the intestine, where microorganisms can deconjugate and transform them into diverse secondary bile acids. These compounds interact with receptors such as farnesoid X receptor (FXR) and G protein-coupled bile acid receptor 1 (TGR5), thereby influencing hepatic metabolism, energy expenditure, intestinal signaling, and enteroendocrine hormone secretion [52,53].

Changes in microbial bile-acid transformation have been linked to T2DM and related cardiometabolic disorders, although the causal pathways vary according to bile-acid species and tissue context. Gao et al. [54] highlighted the reciprocal nature of bile acid–microbiota signaling in glucose regulation.

This pathway has rarely been investigated in relation to OPP and therefore represents a research opportunity. If OPP modifies microbial composition or enzymatic activity, secondary bile-acid pools could change even without direct interaction between OPP and bile-acid receptors. Targeted bile-acid metabolomics would therefore add considerable mechanistic value to future human studies.

Phenolic Microbial Metabolites

Microbial conversion of polyphenols produces a wide spectrum of smaller aromatic compounds. These include hydroxyphenylpropionic acids, hydroxyphenylacetic acids, benzoic-acid derivatives, and other compounds whose structure

depends on the original polyphenol and microbial enzymatic pathways [41].

Phenolic metabolites may have greater systemic availability than their parent compounds. This makes them plausible mediators of vascular, hepatic, inflammatory, and metabolic effects. Importantly, substantial interindividual variation can occur because not every microbiome possesses the same metabolic pathways [25].

The detection of 3-(3-hydroxyphenyl) propionic acid after fermentation of palm-derived phenolic residue is therefore important beyond the identification of a single metabolite. It demonstrates that palm phenolics can enter microbial biotransformation pathways and provides a candidate biomarker for future work [40].

The gastrointestinal transformation sequence that can reshape OPP exposure is summarized in Figure 3. The biologically relevant exposure after supplementation is unlikely to consist solely of the compounds present in the original formulation because host metabolism and microbial biotransformation can substantially alter the chemical profile reaching systemic tissues.

Figure 3 also identifies the analytical compartments that should be linked in a rigorous pharmacokinetic study, including the administered OPP fingerprint and plasma, urine and fecal metabolomes. Metabolites that show marked between-person variation deserve particular attention because they may help define biologically meaningful responder and non-responder phenotypes.




Figure 3: Gastrointestinal biotransformation of OPP.

Method

Review design

This study employed a critical qualitative literature review. The approach was selected because the evidence relevant to the proposed OPP–microbiome–metabolic axis spans heterogeneous research designs, including chemical characterization, process engineering, cell and animal experiments, ex vivo fecal fermentation, phase I human research, nutritional randomized controlled trials, microbiome cohort studies, pharmacological studies, and mechanistic reviews. A systematic review methodology would be poorly suited to integrating these diverse evidence types into a single translational model without narrowing the research question substantially.

Accordingly, this review did not claim exhaustive retrieval of all publications, did not employ meta-analysis, and did not use PRISMA to imply systematic comprehensiveness. Instead, literature was purposively identified and critically synthesized according to relevance to the proposed mechanistic pathway.

Literature identification

The principal evidence window was January 2020 to September 2026. Literature was identified from PubMed/MEDLINE, Scopus, Web of Science, ScienceDirect, and major journal-publisher databases. Search concepts included combinations of “oil palm phenolics”, “palm phenolics”, “oil palm aqueous by-products”, “palm mill”, “polyphenols”, “gut microbiota”, “gut microbiome”, “metabolic endotoxemia”, “lipopolysaccharide”, “intestinal permeability”, “intestinal barrier”, “obesity”, “type 2 diabetes”, “insulin resistance”, “SCFA”, “bile acids”, “phenolic metabolites”, “metformin”, “GLP-1 receptor agonist”, “precision nutrition”, “metagenomics”, and “metabolomics”.

Priority was given to peer-reviewed journal articles from reputable international journals, particularly primary studies and contemporary reviews published from 2020 onward. Older landmark studies were considered conceptually during interpretation but were deliberately excluded from the formal reference list in order to maintain the requested contemporary evidence window.

Evidence hierarchy

Evidence was classified into four translational levels to distinguish direct OPP evidence from mechanistic extrapolation. This structure was used to prevent findings from broader polyphenol or microbiome research from being presented as if they were direct demonstrations of OPP efficacy.

Level A comprised direct human OPP evidence, including studies in which a chemically defined OPP preparation was administered to human participants. This level was assigned the greatest translational relevance for statements about human safety, exposure, or efficacy.

Level B comprised direct palm-derived phenolic microbiome

evidence, including experimental studies evaluating palm-derived phenolics in human-origin microbiota or related biological systems. These studies were considered highly relevant for mechanistic plausibility but insufficient on their own to establish clinical benefit.

Level C comprised human evidence from other dietary polyphenols and polyphenol-rich foods. These studies were used as mechanistic analogues for potential microbiome, barrier, metabolite, or inflammatory effects and were not treated as proof of OPP efficacy.

Level D comprised animal, cellular, ex vivo, and other mechanistic evidence used to identify plausible pathways and candidate biomarkers. Findings at this level were interpreted as hypothesis-supporting evidence that requires confirmation in appropriately designed human OPP studies.

The hierarchy is necessary because direct OPP evidence remains substantially smaller than the broader dietary-polyphenol literature. It also provides a transparent basis for grading the confidence that can be placed in each proposed link of the translational pathway.

Thematic synthesis

The retrieved literature was synthesized under eight interrelated domains: (1) OPP origin and standardization; (2) gastrointestinal fate and microbial transformation; (3) microbial ecological modulation; (4) intestinal-barrier function; (5) metabolic endotoxemia; (6) SCFAs, bile acids, and phenolic metabolites; (7) insulin resistance and drug–microbiome interactions; and (8) precision metabolic nutrition. The domains were treated as an interconnected evidence network rather than as independent topics, allowing findings from chemistry, microbiology, intestinal physiology and metabolic medicine to be compared within a common translational framework.

Contradictory findings were retained rather than harmonized artificially. Particular attention was given to cases in which microbial changes occurred without parallel improvement in body weight or glycemic markers. This approach was intended to avoid equating microbiome modulation with clinical benefit.

Results: Thematic Findings

Theme 1: OPP has crossed the first human-safety threshold but not the efficacy threshold

The most robust direct human evidence concerns safety rather than metabolic treatment. Muhammad Ismail Tadj et al. [39] randomized 100 healthy adults aged 20–40 years to placebo or OPP doses of 250, 1,000, or 1,500 mg/day for two months. Hematological, liver, renal, vital-sign, and adverse-event assessments did not reveal serious safety concerns attributable to supplementation. The study therefore provides an important initial human exposure benchmark.

The study does not, however, establish clinical efficacy. Participants were healthy, intervention duration was relatively short, and the study was not powered around HbA1c, insulin resistance,

hepatic fat, adipose inflammation, intestinal permeability, or microbiome endpoints. Using this trial to describe OPP as an antidiabetic intervention would therefore represent a substantial overinterpretation.

The evidence base is consequently positioned between preclinical promise and clinical proof. This stage is scientifically valuable because many phytochemical interventions never develop a standardized formulation or human safety dataset. OPP has progressed beyond purely chemical or animal research, but it has not yet crossed the critical proof-of-mechanism threshold in people with metabolic disease.

Theme 2: Direct palm-derived microbiome evidence is promising but still experimental

The strongest direct microbiome evidence is provided by Chuaykarn et al. [40]. In an experimental system using obese-human fecal microbiota, palm-oil phenolic residue changed microbial community characteristics and metabolite profiles. The production of 3-(3-hydroxyphenyl)propionic acid provided direct evidence of microbial biotransformation.

This finding is important for three reasons. First, it validates the proposition that palm-derived phenolic compounds can act as microbial substrates. Second, it provides potential metabolites for targeted measurement in future human studies. Third, it connects OPP research with a rapidly expanding literature showing that microbiome-derived phenolic metabolites may be biologically relevant independently of their parent compounds.

Nevertheless, fecal fermentation removes many components of the intact organism. It does not replicate gastric digestion, small-intestinal absorption, epithelial uptake, host conjugation, enterohepatic cycling, immune responses, endocrine signals, intestinal transit, or medication exposure. Direct clinical translation therefore requires in vivo pharmacokinetic and microbiome studies.

Theme 3: Polyphenol effects are more consistent at intermediate mechanistic endpoints than at body weight

The broader polyphenol literature provides a valuable analogue. Human trials and meta-analyses increasingly indicate that polyphenol supplementation can modify gut microbial composition and microbial metabolites, yet reductions in body weight are inconsistent [27,30,31].

González-Gómez et al. [31] reported significant reductions in circulating LPS and increases in butyrate and acetate across selected randomized trials in overweight or obese participants, while no significant pooled changes occurred in BMI or body weight. This dissociation is highly relevant to trial design. A compound may alter barrier or microbial function without producing sufficient energy deficit to reduce body mass.

Similarly, Alshatari and Ziarno [32] found favorable microbiome

and SCFA patterns across 50 randomized controlled trials, but emphasized methodological heterogeneity and the lack of direct evidence that microbiome changes themselves caused clinical improvements. Wang et al. [33] likewise identified intervention duration, dosage, and food matrix as factors affecting inflammatory and microbial responses.

The implication for OPP is clear: an early clinical trial should prioritize proof-of-mechanism rather than weight loss. Body mass, waist circumference, and body composition remain important secondary outcomes, but they are too distal to determine whether OPP engages the hypothesized microbiome–barrier pathway.

Theme 4: Barrier function is a plausible intermediate target

The intestinal barrier may constitute the most strategically informative intermediate endpoint linking OPP exposure with systemic metabolism. Human T2DM research has reported altered circulating markers consistent with increased epithelial injury or permeability [16]. Broader reviews connect intestinal dysfunction with microbial translocation, immune activation, and metabolic inflammation [17,46].

Polyphenol studies provide mechanistic precedent. Zhang et al. [47] demonstrated that phlorizin improved obesity-associated endotoxemia and insulin resistance while affecting microbiota and barrier integrity in an experimental model. Zhou et al. [48] similarly demonstrated microbiome-dependent anti-obesity effects of Fu brick tea polyphenols, including changes in intestinal oxidative stress and barrier function. Ye et al. [49] linked chlorogenic-acid intervention to microbiome and endotoxemia-related mechanisms.

These interventions are chemically different from OPP, so their effects should not be generalized automatically. Instead, they identify measurable outcomes: tight-junction-related proteins, intestinal permeability, microbial translocation, LPS-related markers, inflammatory pathways, and insulin sensitivity. Direct OPP trials should test these endpoints rather than assuming they change.

Theme 5: SCFAs are plausible mediators but insufficient as standalone biomarkers

SCFAs have received substantial attention as microbial mediators of metabolic health. Butyrate supports colonocyte metabolism and can influence epithelial-barrier maintenance. Acetate and propionate participate in hepatic metabolism, peripheral signaling, and enteroendocrine pathways. SCFAs can also interact with receptors such as FFAR2 and FFAR3 and influence GLP-1 and peptide YY signaling [50,55].

However, interpreting fecal SCFA concentrations is complex. High fecal levels may reflect enhanced production, reduced absorption, rapid transit, altered utilization, or a combination of these factors. Consequently, fecal SCFAs should ideally be interpreted alongside plasma concentrations, microbial functional pathways, stool transit information, and metabolic endpoints.

This nuance is relevant because different polyphenol meta-analyses have reached somewhat different conclusions regarding SCFAs. Mao et al. [30] found no consistent aggregate change in some SCFA analyses, whereas González-Gómez et al. [31] and Alshatari and Ziarno [32] found evidence of increases, particularly for butyrate. Rather than representing irreconcilable findings, these differences likely reflect variation in included trials, health status, duration, matrix, dose, and measurement methods.

Theme 6: The metabolite network extends beyond SCFAs

The microbiome generates or modifies numerous metabolites relevant to metabolic health. Secondary bile acids interact with FXR and TGR5 pathways and can influence glucose metabolism, hepatic lipid regulation, and enteroendocrine signaling [52-54].

Tryptophan-derived indoles can influence epithelial and immune signaling, whereas phenolic microbial metabolites may reach systemic circulation in concentrations greater than some parent phytochemicals. The gut microbiome therefore acts as a biochemical transformation system whose effects depend on both substrate availability and microbial enzymatic capacity [41,55].

Not all microbial metabolites are beneficial. Koh et al. [56] demonstrated that imidazole propionate can interfere with metformin-associated AMPK activation. This finding is conceptually important because it shows that the microbiome can generate metabolites that worsen metabolic signaling or reduce pharmacological responsiveness.

The desirable OPP response should therefore not be defined as simply “increasing microbial diversity” or “increasing SCFAs”. The more meaningful endpoint is a favorable reconfiguration of microbial functional output.

Theme 7: Dietary context materially shapes polyphenol responses

Polyphenols are rarely consumed in isolation outside supplementation trials. Food matrix and dietary background affect their solubility, gastric processing, intestinal absorption, microbial fermentation, and the substrates available for microbial cross-feeding. Dietary fiber may be particularly important because fermentable carbohydrates influence SCFA-producing ecosystems and can interact with polyphenol metabolism. This dependence on fermentable substrate availability and food matrix is consistent with recent evidence that dietary fibre can alter microbial fermentation, barrier biology and metabolic outcomes in obesity [57].

Controlled dietary studies support this systems perspective. Meslier et al. [58] found that a Mediterranean-diet intervention modified the gut microbiome and metabolome in overweight and obese adults independently of energy intake. Ghosh et al. [59] observed microbiome changes after a Mediterranean-diet intervention in older adults across several European populations. Rinott et al. [60] linked Green-Mediterranean dietary effects with microbiome modification, while Wastyk et al. [61] demonstrated

that microbiota-targeted diets can change host immune status.

Human polyphenol interventions provide more specific comparators. Hou et al. [62] found that pomegranate juice combined with inulin produced microbiota and metabolite changes in overweight or obese adults despite limited short-term change in conventional anthropometric and biochemical outcomes. This pattern illustrates why OPP may require a mechanistic endpoint strategy rather than expecting immediate weight reduction.

Experimental studies using pomegranate polyphenols, tea polyphenols, berries, and other polyphenol-rich products have also reported interactions among microbial composition, barrier function, adiposity, and insulin-related outcomes [63-66]. These studies provide mechanistic comparators but not substitutes for OPP-specific evidence.

Theme 8: Pharmacotherapy is part of the microbiome environment

patients with T2DM receiving OPP in future trials will often be taking metformin, GLP-1 receptor agonists, SGLT2 inhibitors, statins, antihypertensives, or other medications. Some of these drugs modify intestinal physiology or microbial ecology. This complicates causal interpretation but also creates opportunities to study nutrient–drug–microbiome interactions.

Mueller et al. [67] demonstrated in a randomized trial that metformin changed microbial composition, microbial functional pathways, and circulating SCFAs. Nakajima et al. [68] similarly reported changes in microbiota among patients treated with metformin. At the same time, the discovery that imidazole propionate can attenuate aspects of metformin signaling illustrates how microbial metabolites may alter drug action [56].

GLP-1 receptor agonists create another relevant context. Liraglutide-associated microbiome modulation has been reported in human and experimental studies [69,70], while more recent experimental evidence suggests that semaglutide can alter high-fat-diet-associated dysbiosis [71].

Future OPP studies should therefore record and stratify important medications rather than treating them merely as uncontrolled background variables. A response observed only among metformin users, for example, could indicate either confounding or a meaningful drug–microbiome–phenolic interaction.

Discussion and Analysis

The central synthesis: from OPP ingestion to metabolic signaling. The evidence reviewed supports a coherent but incomplete mechanistic chain. The first link—chemical availability of palm-derived phenolics—is established through analytical research. The second—human exposure to standardized OPP—has been demonstrated through phase I research. The third—interaction of palm phenolics with human-origin microbiota—is supported by ex vivo experimentation. The subsequent links involving intestinal-barrier improvement, reduced metabolic endotoxemia, lower

tissue inflammation, and improved insulin sensitivity are currently supported mainly by mechanistically analogous polyphenol and microbiome literature rather than direct OPP trials.

This evidence structure is scientifically valuable because it identifies exactly where translation is incomplete. The critical gap is not whether phenolics can influence microorganisms in principle; that is well supported. The gap is whether a chemically standardized OPP intervention produces a reproducible sequence of microbial and host changes in metabolically unhealthy humans.

A robust test of the proposed OPP axis would therefore require evidence of temporality. OPP-associated microbial or metabolomic alterations should occur before, or at least concomitantly with, measurable improvement in barrier and metabolic markers. If insulin sensitivity improves without detectable microbiome changes, a primarily microbiome-mediated model would be weakened. Conversely, if the microbiome changes but barrier and metabolic endpoints remain unchanged, microbial modulation alone would be insufficient to explain therapeutic value.

Why OPP should not be framed merely as an antioxidant

The antioxidant paradigm remains relevant because OPP contains phenolic compounds capable of influencing oxidative and inflammatory processes. However, describing OPP primarily through antioxidant capacity risks reducing a complex biological mixture to a nonspecific mechanism shared by hundreds of plant products.

Microbiome-mediated biotransformation provides a more distinctive and experimentally productive hypothesis. It predicts that the biological response depends partly on microbial enzymatic capacity, that different metabolites should appear across individuals, and that responder status may be predicted from baseline microbial features. These are testable propositions that go beyond generic claims of oxidative-stress reduction.

This framework also explains why parent-compound bioavailability may underestimate biological exposure. If microbial metabolism generates readily absorbed phenolic acids, the biologically active systemic compounds after OPP ingestion may differ substantially from the compounds initially measured in the supplement [22,25].

An integrated interpretation is therefore preferable: OPP may exert direct host effects, microbiome-dependent effects, and effects mediated by interactions between the two. Future causal work should attempt to partition these components.

The intestinal barrier as the pivotal intermediate node

Among the proposed intermediate mechanisms, barrier function deserves particular priority because it occupies the anatomical interface between OPP, microbiota, and host metabolism. A compound that alters microbial ecology but fails to modify host exposure to microbial products may have limited systemic effects. Conversely, a relatively small microbial change could be

metabolically meaningful if it substantially strengthens epithelial integrity or reduces exposure to strongly pro-inflammatory LPS.

Future clinical studies should therefore employ complementary barrier markers rather than a single assay. Potential endpoints include orally administered permeability probes, circulating intestinal fatty-acid-binding protein, LPS-binding protein, selected tight-junction-related markers, inflammatory mediators, and microbiome functional measures. Zonulin-related assays may be included cautiously because commercial assays differ in analytical specificity.

Integration is more important than any single biomarker. A convincing OPP-associated barrier effect would consist of concordant changes across permeability, endotoxemia, microbial function, and systemic inflammation.

A functional rather than taxonomic microbiome model

Early microbiome literature often emphasized diversity indices or the Firmicutes-to-Bacteroidetes ratio. Contemporary evidence suggests that such measures are too coarse for precision metabolic research. Mei et al. [12] identified strain-specific T2DM associations, while broader work has demonstrated that microbial pathways and metabolites may be more stable or mechanistically informative than broad taxonomic categories.

Consequently, future OPP trials should preferably use shotgun metagenomics rather than relying exclusively on 16S rRNA sequencing. Relevant functions include genes involved in phenolic transformation, butyrate production, bile-acid metabolism, aromatic amino-acid metabolism, LPS biosynthesis, mucin utilization, and carbohydrate fermentation.

Metatranscriptomics would add further value by distinguishing the microbial genes present from those actively expressed during OPP intervention. However, because cost and complexity increase substantially, an efficient first-stage human study could combine shotgun metagenomics with targeted metabolomics.

Metabolomics as the bridge between microbiome and host

Microbiome sequencing alone cannot determine whether a pathway is functionally active. Metabolomics can help bridge this gap by measuring the chemical products generated by microbial and host metabolism. For OPP, three metabolomic layers are particularly important: phenolic metabolites, SCFAs, and bile acids.

Targeted phenolic metabolomics could determine which parent OPP compounds and microbial derivatives reach circulation. Repeated sampling after acute dosing could establish time-to-peak and elimination patterns, whereas longer supplementation could identify adaptation of the microbial metabolic response.

A key objective should be to identify candidate biomarkers of OPP biotransformation. The microbial formation of 3-(3-hydroxyphenyl) propionic acid observed experimentally

provides one starting point, but additional metabolites are likely. Rather than assuming that all generated metabolites are beneficial, each candidate should be evaluated against host signaling pathways and metabolic outcomes.

SCFA and bile-acid profiling could then determine whether OPP alters broader microbial metabolism beyond phenolic conversion. This multi-metabolite approach would provide a much richer mechanistic model than measurement of total phenolics or antioxidant capacity alone.

Evidence from microbiota-targeted interventions supports causal plausibility

One challenge in microbiome research is distinguishing association from causality. Obesity and T2DM can alter diet, gastrointestinal physiology, medications, and metabolism, all of which can themselves change the microbiome. Therefore, observing a microbial difference between diabetic and non-diabetic individuals does not prove that the difference contributes to diabetes.

Interventional evidence offers stronger support. Mocanu et al. [72] conducted a randomized phase II trial combining fecal microbial transplantation with different fiber conditions in participants with severe obesity and metabolic syndrome. Improvement in insulin-sensitivity measures in one intervention arm provided proof of concept that deliberate microbial ecological manipulation can alter host metabolic outcomes.

However, fecal microbial transplantation represents a much stronger ecological perturbation than a polyphenol supplement. OPP would more plausibly exert subtle selective pressure on existing communities rather than replace them. Its expected effect size may consequently be smaller and more dependent on baseline microbial structure.

The study nevertheless establishes an important principle: microbiome modification can, under appropriate conditions, be connected experimentally with insulin sensitivity. The challenge for OPP is to demonstrate that a dietary phenolic intervention can achieve a reproducible version of this relationship.

Interaction with metformin: confounder and mechanistic opportunity

Metformin is especially relevant because it is widely used in T2DM and acts partly within the gastrointestinal environment. Mueller et al. [67] demonstrated long-term changes in microbiome composition and microbial functional pathways during metformin treatment, including pathways associated with acetate and glucose metabolism.

Consequently, a trial that enrolls a mixture of metformin users and non-users without stratification could misattribute drug-associated microbial signatures to OPP. Stable medication status should therefore be required before randomization, and metformin exposure should be an a priori stratification variable.

The interaction could also be therapeutically meaningful. If OPP

altered production of microbial metabolites such as imidazole propionate or changed microbial pathways influencing AMPK-associated signaling, it might modify metformin responsiveness. This possibility is speculative but experimentally testable.

Rather than excluding all medicated patients, a staged program could first test OPP in participants with stable diet-controlled prediabetes and subsequently investigate interaction with metformin in T2DM. This sequence would preserve mechanistic clarity in early studies while improving the clinical relevance of later trials.

GLP-1 receptor agonists and the changing clinical landscape

The rapid expansion of GLP-1 receptor agonist therapy complicates the design of future nutritional studies because these drugs strongly affect appetite, gastric emptying, weight, glycemic regulation, and potentially microbial ecology. Liraglutide-associated microbiome changes have already been described, and experimental semaglutide research suggests possible effects on diet-induced dysbiosis [69-73].

If OPP is studied in patients taking GLP-1 receptor agonists, a reduction in weight or improved glycemia cannot readily be attributed to OPP unless pharmacotherapy is stable and adequately controlled. Moreover, changes in food intake caused by GLP-1 therapy could themselves alter the microbiome.

Future trials should therefore prespecify GLP-1 receptor agonist use, document dose stability, measure dietary intake, and consider stratified analyses. The same logic applies to antibiotics, proton-pump inhibitors, laxatives, and other exposures capable of modifying intestinal ecology.

OPP as precision metabolic nutrition

The strongest long-term conceptual positioning for OPP may be precision metabolic nutrition rather than a universally effective supplement. Human postprandial studies demonstrate considerable individual variation in glucose, insulin, and lipid responses to identical meals. Berry et al. [14] showed that person-specific characteristics, including microbiome features, contribute to these differences, while Asnicar et al. [15] linked habitual diet, microbial composition, and cardiometabolic phenotypes in more than 1,000 deeply phenotyped individuals.

Precision nutrition does not imply that a microbiome algorithm can already prescribe an optimal OPP dose. Instead, it provides an analytical framework for understanding heterogeneity. Individuals may differ in their ability to convert OPP phenolics into candidate active metabolites. Such differences could be influenced by microbial species, strain-level genes, habitual fiber intake, prior polyphenol exposure, metabolic state, and medication use [13,74,75].

An OPP “metabotype” could therefore be defined by the metabolic products generated after a standardized challenge. For example,

high responders might produce a characteristic set of phenolic metabolites accompanied by reduced LPS-binding protein and improved insulin sensitivity. Low responders might show limited biotransformation or produce a different metabolite spectrum.

This concept can be tested experimentally without assuming that one microbial taxon determines response. It also aligns with the strain-level complexity demonstrated in contemporary T2DM microbiome research.

Figure 4 integrates the major determinants that could produce heterogeneous responses to OPP in a precision-nutrition framework. In this model, baseline microbial, dietary, pharmacological and metabolic heterogeneity is treated as biologically informative rather than as statistical noise.

Figure 4 emphasizes that OPP response is likely to depend on interactions among ingredient chemistry, microbial capacity, habitual diet, medication exposure and host phenotype. Future precision-nutrition studies should therefore first establish reproducible biological response patterns and only subsequently attempt to develop predictive algorithms.

Lessons from other polyphenol-rich interventions

Research with other polyphenols offers methodological guidance. Pomegranate provides one relevant example because ellagitannins and related compounds are extensively metabolized by gut microorganisms, producing highly individual metabolite patterns. Hou et al. [62] demonstrated that pomegranate juice with inulin could alter microbial composition and microbiota-associated

metabolites within weeks in adults with overweight or obesity without necessarily producing major short-term anthropometric changes.

Experimental studies using pomegranate fruit pulp or peel polyphenols have also reported reduced diet-induced obesity and insulin-resistance-related phenotypes alongside microbiota modification [64,65]. These findings illustrate how metabolically relevant effects can occur through combined host and microbial pathways.

Tea polyphenols provide another model. Green tea polyphenols have demonstrated microbial and intestinal-inflammatory effects in high-fat-diet models, while Fu brick tea polyphenols have been investigated using microbiota-transfer experiments that support partial microbiome dependence [63,48].

Berry interventions provide additional evidence of human heterogeneity. Reviews of randomized berry-polyphenol studies report microbiome changes but substantial variation according to berry type, dose, study duration, participant characteristics, and analytical methods [66].

The lesson for OPP is methodological rather than predictive. A complex phenolic mixture should be studied with rigorous chemical characterization, controlled background diet, repeated microbiome and metabolome sampling, and mechanistic outcomes. Findings from pomegranate, tea, berries, or chlorogenic acid establish plausibility but cannot determine the magnitude or direction of OPP effects.




Figure 4: Precision metabolic nutrition framework for OPP.

Why body weight should not be the primary early endpoint

A common problem in nutritional intervention research is the expectation that a metabolically relevant compound must produce visible weight loss. For OPP, such an expectation would be especially inappropriate because the proposed mechanism does not require major reduction in energy intake.

If OPP primarily alters microbial metabolism, barrier integrity, or low-grade inflammation, early benefits may be reflected in insulin sensitivity, postprandial glucose, endotoxemia, or inflammatory tone before changes in body mass occur. González-Gómez et al. [31] provide an instructive example in which LPS and SCFA-related effects occurred without significant pooled weight reduction.

More broadly, recent meta-analyses and evidence syntheses report statistically significant but generally modest cardiometabolic and anthropometric effects of polyphenol interventions, reinforcing that polyphenols should not be conceptualized as high-magnitude weight-loss agents. Early OPP research should therefore avoid defining success or failure solely around kilograms of weight lost [30-33].

This distinction also has regulatory implications. Positioning OPP as a metabolic-health ingredient requires clinically relevant but realistic outcomes. Improved insulin sensitivity or reduced metabolic-endotoxemia markers may represent meaningful proof of mechanism without constituting evidence that OPP treats obesity.

Proposed human research program

A staged research program would reduce uncertainty efficiently. Each phase should answer a distinct translational question before the next phase expands the population, duration, or clinical ambition of the intervention.

Phase A: Chemical and manufacturing standardization

The first priority is to establish a reproducible OPP product. Manufacturing specifications should define the source stream, extraction conditions, concentration method, marker phenolics, residual solvents where relevant, contaminants, microbiological quality, stability, and storage conditions. Multiple production batches should be compared using high-resolution analytical chemistry.

Phase B: Human pharmacokinetics and metabotyping

Healthy participants could receive standardized acute and repeated OPP doses. Plasma, urine, and stool should be collected over predefined intervals to identify parent compounds, host conjugates, and microbiota-derived metabolites. This phase would determine which metabolites are consistently generated, which exhibit high interindividual variability, and whether metabolite patterns change after repeated exposure.

Phase C: Dose-ranging mechanistic study

Adults with obesity and insulin resistance could be randomized to placebo and at least two OPP doses. Outcomes should include microbiome function, phenolic metabolites, SCFAs, bile acids, barrier markers, endotoxemia, inflammatory biomarkers, fasting insulin, and dynamic glucose handling.

The purpose would not be to identify a maximum tolerated dose—the phase I study already provides preliminary information on tolerability—but to identify a biologically active dose. A lower dose could theoretically be more favorable if higher concentrations produce different microbial ecological effects.

Phase D: Proof-of-mechanism trial in prediabetes or early T2DM

A 12–16-week randomized, double-blind, placebo-controlled study represents the most important next translational step. Participants should have stable medication and dietary patterns, with metformin use prespecified.

The primary endpoint should be mechanistic, potentially a composite or hierarchical set consisting of insulin sensitivity plus microbiome/metabolome changes. Secondary outcomes could include HbA1c, fasting glucose, OGTT-derived indices, weight, waist circumference, lipid profile, hepatic-fat markers, inflammatory biomarkers, and patient-reported gastrointestinal tolerability.

Phase E: Disease-efficacy trial

Only if the proof-of-mechanism phase demonstrates a reproducible signal should larger T2DM trials be undertaken. Such studies would require clinically meaningful endpoints and adequate duration to assess HbA1c, medication requirements, progression, and longer-term safety.

The staged translational evidence pathway for OPP is summarized in Figure 5. The ladder distinguishes chemical characterization, experimental mechanism, human safety, proof-of-mechanism and disease efficacy as separate milestones, and it shows that the current evidence base has not yet completed the clinical-efficacy stages.

Figure 5 illustrates why sequential development can reduce the risk of undertaking large efficacy trials before the biologically active dose, microbial metabolites, target pathways and responder characteristics are understood. The same sequence also provides a more defensible evidence base for subsequent regulatory assessment and commercial health claims.

Proposed design of a definitive proof-of-mechanism trial

A particularly informative study could enroll approximately 120–180 adults with obesity and either prediabetes or recently diagnosed T2DM. Participants would be randomized to placebo, lower-dose standardized OPP, or higher-dose standardized OPP for 12–16 weeks. Stable medication for an adequate run-in period should




Figure 5: Translational evidence ladder for OPP.

be required, while recent antibiotic exposure should constitute an exclusion criterion because it could substantially alter baseline microbial ecology.

The trial should standardize the OPP preparation by LC-MS/MS fingerprint and quantify several marker compounds. Adherence should be assessed not only by capsule counts but, if feasible, through circulating or urinary phenolic-metabolite biomarkers.

Stool would be collected at baseline, an early time point, mid-intervention, and study completion. Shotgun metagenomic sequencing would quantify species, strains, and microbial pathways. Targeted analysis would examine genes involved in phenolic transformation, SCFA production, bile-acid metabolism, aromatic amino-acid metabolism, and LPS biosynthesis.

Plasma and urine metabolomics should quantify parent phenolics

and microbial-derived phenolic acids. SCFAs should be measured in stool and, where analytically feasible, circulation. Targeted bile-acid profiling would assess primary, conjugated, and secondary bile-acid species.

Barrier endpoints could include validated sugar-permeability tests, LPS-binding protein, intestinal fatty-acid-binding protein, and a carefully selected panel of epithelial and inflammatory biomarkers. Systemic inflammation could be assessed with hs-CRP, IL-6, TNF-related measures, and other prespecified indicators.

Metabolic outcomes should include fasting glucose and insulin, HOMA-IR, HbA1c, and a standardized OGTT. In a mechanistic subgroup, a hyperinsulinemic-euglycemic clamp would provide a substantially stronger measure of insulin sensitivity than HOMA-IR alone.

Most importantly, the analysis should test mediation. If OPP improves insulin sensitivity, investigators should determine whether changes in specific microbial pathways or metabolites statistically mediate the effect. This would transform the study from a conventional supplement trial into a mechanistic translational experiment.

Broader Implications

Implications for circular bioeconomy

The conversion of aqueous palm-processing side streams into a standardized bioactive ingredient would represent a form of biochemical upcycling. Instead of evaluating palm-industry sustainability solely through waste reduction, energy recovery, or fertilizer production, OPP creates the possibility of obtaining higher-value compounds from material that would otherwise require treatment.

This approach could diversify product portfolios within palm-producing countries and strengthen downstream oleochemical and nutraceutical innovation. However, economic feasibility would depend on recovery yields, purification requirements, standardization costs, market size, regulatory classification, intellectual-property considerations, and the ability to demonstrate clinically meaningful benefit.

A health-oriented valorization strategy should therefore be integrated with environmental life-cycle analysis. It would be counterproductive to describe OPP recovery as circular if purification required disproportionate energy, water, solvents, or waste generation.

Implications for metabolic medicine

The biomedical value of OPP lies less in the discovery of another generic antioxidant supplement and more in its potential as a model for microbiome-aware phytochemical development. If future studies demonstrate reproducible microbial metabolites linked causally to barrier and insulin-signaling improvements, OPP could contribute to a broader transition from conventional supplementation toward mechanism-defined metabolic nutrition.

Such development would also support a more realistic model of nutritional efficacy. Unlike pharmaceutical monotherapy directed at a single receptor, a phenolic mixture may produce modest effects across several interacting pathways. Its clinical value could therefore depend on appropriate population selection and combination with dietary or pharmacological strategies.

Avoiding premature commercial claims

The current evidence does not justify claims that OPP treats T2DM, reverses insulin resistance, repairs the human intestinal barrier, or prevents obesity. These propositions remain hypotheses requiring clinical validation.

The most defensible current terminology is therefore candidate microbiome-active phenolic ingredient, translational metabolic-nutrition candidate, or OPP-derived microbiome-modulating

intervention under investigation. These labels acknowledge the biological rationale without implying therapeutic efficacy that has not yet been demonstrated in humans.

This restraint is not a weakness. On the contrary, it strengthens the scientific argument by clearly identifying what has been demonstrated and what remains to be tested.

Conclusion

Oil palm phenolics represent an unusually interdisciplinary research opportunity linking palm-processing side-stream valorization with contemporary microbiome and metabolic science. The available evidence demonstrates that hydrophilic phenolics can be identified and recovered from palm-derived matrices, that standardized OPP has reached an initial human safety stage, and that palm-derived phenolic material can undergo interaction and biotransformation within obese-human fecal microbial communities.

The major translational gap lies beyond these observations. Clinical evidence has not yet demonstrated that OPP improves insulin resistance, glycemic control, intestinal-barrier integrity, metabolic endotoxemia, or obesity-related outcomes in humans. The proposed OPP–microbiome–intestinal barrier–metabolic inflammation–insulin resistance axis should therefore be treated as a research framework rather than a confirmed therapeutic mechanism.

The most productive development strategy is sequential. OPP preparations first require rigorous chemical standardization and human pharmacokinetic characterization. These steps should be followed by microbiome- and metabolome-integrated dose-finding studies and mechanistic randomized trials in obesity, prediabetes, or early T2DM. Only after reproducible biological effects have been demonstrated should large therapeutic-efficacy studies and precision-nutrition implementation be prioritized.

This evidence pathway also provides a broader lesson for agricultural bioactive development. Circularity can generate promising candidate compounds, but responsible translation requires that environmental value, chemical reproducibility, biological mechanism, and clinical efficacy be demonstrated independently before they are combined into a commercial health proposition. If this progression is achieved, OPP could provide a distinctive example of how an agricultural processing side stream may be transformed into a scientifically characterized, microbiome-aware component of precision metabolic nutrition.

References

1. Xourafa G, Korbmacher M, Roden M. Inter-organ crosstalk during development and progression of type 2 diabetes mellitus. *Nat Rev Endocrinol.* 2024; 20: 27-49.
2. Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. *Nat Rev Microbiol.* 2021; 19: 55-71.
3. Massey W, Brown JM. The gut microbial endocrine organ in type 2 diabetes. *Endocrinology.* 2021; 162: 235.

4. Howard EJ, Lam TKT, Duca FA. The gut microbiome: Connecting diet, glucose homeostasis, and disease. *Annu Rev Med.* 2022; 73: 469-481.
5. Baars DP, Marcos FF, Abraham SM, et al. The central role of the gut microbiota in the pathophysiology and management of type 2 diabetes. *Cell Host Microbe.* 2024; 32: 1280-1300.
6. Crovesy L, Masterson D, Rosado EL. Profile of the gut microbiota of adults with obesity: a systematic review. *Eur J Clin Nutr.* 2020; 74: 1251-1262.
7. Umirah F, Neoh CF, Ramasamy K, et al. Differential gut microbiota composition between type 2 diabetes mellitus patients and healthy controls: A systematic review. *Diabetes Res Clin Pract.* 2021; 173: 108689.
8. Iatcu CO, Steen A, Covasa M. Gut microbiota and complications of type-2 diabetes. *Nutrients.* 2022; 14: 166.
9. De Vos WM, Tilg H, Van Hul M, et al. Gut microbiome and health: mechanistic insights. *Gut.* 2022; 71: 1020-1032.
10. Van Hul M, Cani PD. The gut microbiota in obesity and weight management: microbes as friends or foe. *Nat Rev Endocrinol.* 2023; 19: 258-271.
11. Carmody RN, Bisanz JE. Roles of the gut microbiome in weight management. *Nat Rev Microbiol.* 2023; 21: 535-550.
12. Mei Z, Fenglei W, Amrisha B, et al. Strain-specific gut microbial signatures in type 2 diabetes identified in a cross-cohort analysis of 8,117 metagenomes. *Nat Med.* 2024; 30: 2265-2276.
13. Leshem A, Segal E, Elinav E. The gut microbiome and individual-specific responses to diet. *mSystems.* 2020; 5: e00665-e00720.
14. Berry SE, Ana MV, David AD, et al. Human postprandial responses to food and potential for precision nutrition. *Nat Med.* 2020; 26: 964-973.
15. Asnicar F, Sarah EB, Ana MV, et al. Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals. *Nat Med.* 2021; 27: 321-332.
16. Yuan JH, Qing SX, Guang CC, et al. Impaired intestinal barrier function in type 2 diabetic patients measured by serum LPS, zonulin, and IFABP. *J Diabetes Complications.* 2021; 35: 107766.
17. Riedel S, Pheiffer C, Johnson R, et al. Intestinal barrier function and immune homeostasis are missing links in obesity and type 2 diabetes development. *Front Endocrinol.* 2022; 12: 833544.
18. Yang G, Jinlong W, Pinyi L, et al. Role of the gut microbiota in type 2 diabetes and related diseases. *Metabolism.* 2021; 117: 154712.
19. Zhou Z, Sun B, Yu D, et al. Gut microbiota: An important player in type 2 diabetes mellitus. *Front Cell Infect Microbiol.* 2022; 12: 834485.
20. Islam T, Kembra AS, Latha R, et al. Anti-inflammatory mechanisms of polyphenols in adipose tissue: role of gut microbiota, intestinal barrier integrity and zinc homeostasis. *J Nutr Biochem.* 2023; 115: 109242.
21. Anhê FF, Nicole GB, Joseph FC, et al. Metabolic endotoxemia is dictated by the type of lipopolysaccharide. *Cell Rep.* 2021; 36: 109691.
22. Wang X, Qi Y, Zheng H. Dietary polyphenol, gut microbiota, and health benefits. *Antioxidants.* 2022; 11: 1212.
23. Perla LF, João PNM, Lucas MF, et al. Plant-derived (poly) phenols and their metabolic outcomes: The pursuit of a role for the gut microbiota. *Nutrients.* 2022; 14: 3510.
24. Lippolis T, Miriam C, Giusy RC, et al. Bioaccessibility and bioavailability of diet polyphenols and their modulation of gut microbiota. *Int J Mol Sci.* 2023; 24: 3813.
25. Cheng H, Dandan Z, Jing W, et al. Interactions between gut microbiota and polyphenols: A mechanistic and metabolomic review. *Phytomedicine.* 2023; 119: 154979.
26. Yen GC, Cheng HL, Lin LY, et al. The potential role of phenolic compounds on modulating gut microbiota in obesity. *J Food Drug Anal.* 2020; 28: 195-205.
27. Moorthy M, Chaiyakunapruk N, Jacob SA, et al. Prebiotic potential of polyphenols, its effect on gut microbiota and anthropometric/clinical markers: A systematic review of randomised controlled trials. *Trends Food Sci Technol.* 2020; 99: 634-649.
28. Duarte L, Naschla G, Carlos P, et al. Polyphenols and their anti-obesity role mediated by the gut microbiota: a comprehensive review. *Rev Endocr Metab Disord.* 2021; 22: 367-388.
29. Molinari R, Merendino N, Costantini L. Polyphenols as modulators of pre-established gut microbiota dysbiosis: State-of-the-art. *BioFactors.* 2022; 48: 255-273.
30. Mao T, Zhang Y, Kaushik R, et al. Effects of polyphenols on gut microbiota and inflammatory markers in individuals with overweight or obesity: a systematic review and meta-analysis of randomized controlled trials. *Crit Rev Food Sci Nutr.* 2025; 65: 6158-6175.
31. González-Gómez Á, Martina C, Ana MG, et al. Effect of polyphenol-rich interventions on gut microbiota and inflammatory or oxidative stress markers in adults who are overweight or obese: A systematic review and meta-analysis. *Nutrients.* 2025; 17: 2468.
32. Alshatari S, Ziarno M. Effects of polyphenol supplementation on gut microbiota composition and fecal short-chain fatty acids: A systematic review and meta-analysis of randomized controlled trials. *Nutrients.* 2026; 18: 1762.
33. Wang Q, Huimin Z, Zhang Y, et al. Effects of polyphenols on gut health and inflammation in overweight and obese populations: A systematic review and meta-analysis of dose, duration, and food matrix. *Nutr Rev.* 2026; 255.
34. Abdullah F, Ramli NAS. Identification of hydrophilic phenolic compounds derived from palm oil products. *J Oil Palm Res.* 2020; 32: 258-270.
35. Ibrahim NI, Fairus S, Mohamed IN. The effects and potential mechanism of oil palm phenolics in cardiovascular health: A review on current evidence. *Nutrients.* 2020; 12: 2055.

36. González-Díaz A, Pataquiva-Mateus A, García-Núñez JA. Recovery of palm phytonutrients as a potential market for the by-products generated by palm oil mills and refineries-A review. *Food Biosci.* 2021; 41: 100916.
37. Nur MMA, Garcia GM, Boelen P, et al. Influence of photodegradation on the removal of color and phenolic compounds from palm oil mill effluent by *Arthrospira platensis*. *J Appl Phycol.* 2021; 33: 901-915.
38. Putra LS, Johan S, Clairine N, et al. Comparative study of polyphenolic compound extraction from empty palm fruit bunches and sugarcane pulp. *Heliyon.* 2022; 8: e08951.
39. Muhammad Ismail Tadj, Nurul II, Qodriyah HMS, et al. A Phase I, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and tolerance of oil palm phenolics (OPP) in healthy volunteers. *Front Pharmacol.* 2022; 13: 893171.
40. Chuaykarn N, Nattha T, Piyanun W, et al. Comparative effectiveness of indigestible carbohydrates and plant polyphenols on the gut microbiota profile and metabolite alterations of obese patients. *Bioact Carbohydr Diet Fibre.* 2024; 32: 100443.
41. Gade A, Kumar MS. Gut microbial metabolites of dietary polyphenols and their potential role in human health and diseases. *J Physiol Biochem.* 2023; 79: 695-718.
42. Petersen K, Mansell TJ. Unveiling the prebiotic potential of polyphenols in gut health and metabolism. *Curr Opin Biotechnol.* 2025; 95: 103338.
43. Liu J, He Z, Ma N, et al. Beneficial effects of dietary polyphenols on high-fat diet-induced obesity linking with modulation of gut microbiota. *J Agric Food Chem.* 2020; 68: 33-47.
44. Cunningham AL, Stephens JW, Harris DA. Gut microbiota influence in type 2 diabetes mellitus. *Gut Pathog.* 2021; 13: 50.
45. Arora A, Tapan B, Aayush S, et al. Unravelling the involvement of gut microbiota in type 2 diabetes mellitus. *Life Sci.* 2021; 273: 119311.
46. Cani PD, Van Hul M. Gut microbiota in overweight and obesity: crosstalk with adipose tissue. *Nat Rev Gastroenterol Hepatol.* 2024; 21: 164-183.
47. Zhang XY, Jiang C, Kang Y, et al. Phlorizin ameliorates obesity-associated endotoxemia and insulin resistance in high-fat diet-fed mice by targeting the gut microbiota and intestinal barrier integrity. *Gut Microbes.* 2020; 12: 1842990.
48. Zhou F, Long LY, Xin Z, et al. Polyphenols from Fu Brick Tea reduce obesity via modulation of gut microbiota and gut microbiota-related intestinal oxidative stress and barrier function. *J Agric Food Chem.* 2021; 69: 14530-14543.
49. Ye X, Yang L, Jiajin H, et al. Chlorogenic acid-induced gut microbiota improves metabolic endotoxemia. *Front Endocrinol.* 2021; 12: 762691.
50. Lange O, Proczko-Stepaniak M, Mika A. Short-chain fatty acids-A product of the microbiome and its participation in two-way communication on the microbiome-host mammal line. *Curr Obes Rep.* 2023; 12: 108-126.
51. Bany Bakar R, Reimann F, Gribble FM. The intestine as an endocrine organ and the role of gut hormones in metabolic regulation. *Nat Rev Gastroenterol Hepatol.* 2023; 20: 784-796.
52. Callender C, Attaye I, Nieuwdorp M. The interaction between the gut microbiome and bile acids in cardiometabolic diseases. *Metabolites.* 2022; 12: 65.
53. Collins SL, Stine JG, Bisanz JE, et al. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. *Nat Rev Microbiol.* 2023; 21: 236-247.
54. Gao R, Xiangjing M, Yili X, et al. Bile acids-gut microbiota crosstalk contributes to the improvement of type 2 diabetes mellitus. *Front Pharmacol.* 2022; 13: 1027212.
55. Masse KE, Lu VB. Short-chain fatty acids, secondary bile acids and indoles: gut microbial metabolites with effects on enteroendocrine cell function and their potential as therapies for metabolic disease. *Front Endocrinol.* 2023; 14: 1169624.
56. Koh A, Louise MH, Na-Oh Y, et al. Microbial imidazole propionate affects responses to metformin through p38γ-dependent inhibitory AMPK phosphorylation. *Cell Metabolism.* 2020; 32: 643-653.
57. Deehan EC, Mocanu V, Madsen KL. Effects of dietary fibre on metabolic health and obesity. *Nat Rev Gastroenterol Hepatol.* 2024; 21: 301-318.
58. Meslier V, Manolo L, Henrik MR, et al. Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and causes changes in the gut microbiome and metabolome independently of energy intake. *Gut.* 2020; 69: 1258-1268.
59. Ghosh TS, Simone R, Ian BJ, et al. Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries. *Gut.* 2020; 69: 1218-1228.
60. Rinott E, Anat YM, Gal T, et al. The effects of the Green-Mediterranean diet on cardiometabolic health are linked to gut microbiome modifications: a randomized controlled trial. *Genome Med.* 2022; 14: 29.
61. Wastyk HC, Gabriela KF, Dalia P, et al. Gut-microbiota-targeted diets modulate human immune status. *Cell.* 2021; 184: 4137-4153.
62. Hou C, Haidan S, Jingjing X, et al. Pomegranate juice supplemented with inulin modulates gut microbiota and promotes the production of microbiota-associated metabolites in overweight/obese individuals: A randomized, double-blind, placebo-controlled trial. *J Agric Food Chem.* 2024; 72: 14663-14677.
63. Li Y, Sajid UR, Yingying H, et al. Green tea polyphenols decrease weight gain, ameliorate alteration of gut microbiota, and mitigate intestinal inflammation in canines with high-fat-diet-induced obesity. *J Nutr Biochem.* 2020; 78: 108324.

-
64. Song H, Xinchun S, Qiang C, et al. Pomegranate fruit pulp polyphenols reduce diet-induced obesity with modulation of gut microbiota in mice. *J Sci Food Agric*. 2022; 102: 1968-1977.
 65. Song H, Xinchun S, Rou D, et al. Pomegranate peel anthocyanins prevent diet-induced obesity and insulin resistance in association with modulation of the gut microbiota in mice. *Eur J Nutr*. 2022; 61: 1837-1847.
 66. Sweeney M, Gracie B, Nora S, et al. The effects of berry polyphenols on the gut microbiota and blood pressure: A systematic review of randomized clinical trials in humans. *Nutrients*. 2022; 14: 2263.
 67. Mueller NT, Moira KD, Mingyu Z, et al. Metformin affects gut microbiome composition and function and circulating short-chain fatty acids: A randomized trial. *Diabetes Care*. 2021; 44: 1462-1471.
 68. Nakajima H, Fumie T, Yoshitaka H, et al. The effects of metformin on the gut microbiota of patients with type 2 diabetes: A two-center, quasi-experimental study. *Life*. 2020; 10: 195.
 69. Shang J, Fang Liu, Bing Zhang, et al. Liraglutide-induced structural modulation of the gut microbiota in patients with type 2 diabetes mellitus. *Peer J*. 2021; 9: e11128.
 70. Charpentier J, Francois B, Benjamin L, et al. Liraglutide targets the gut microbiota and the intestinal immune system to regulate insulin secretion. *Acta Diabetol*. 2021; 58: 881-897.
 71. Duan X, Lei Zhang, Liao Y, et al. Semaglutide alleviates gut microbiota dysbiosis induced by a high-fat diet. *Eur J Pharmacol*. 2024; 969: 176440.
 72. Mocanu V, Zhengxiao Z, Edward CD, et al. Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial. *Nat Med*. 2021; 27: 1272-1279.
 73. Ansari S, Khoo B, Tan T. Targeting the incretin system in obesity and type 2 diabetes mellitus. *Nat Rev Endocrinol*. 2024; 20: 447-459.
 74. Zheng JS, Ordovás JM. Precision nutrition for gut microbiome and diabetes research: Application of nutritional n-of-1 clinical trials. *J Diabetes*. 2021; 13: 1059-1061.
 75. Jardon KM, Emanuel EC, Gijs HG, et al. Dietary macronutrients and the gut microbiome: a precision nutrition approach to improve cardiometabolic health. *Gut*. 2022; 71: 1214-1226.